On May 12, 2025, Roche announced it plans to invest up to $550 million in its Diagnostics site in Indianapolis by 2030. The site will become a major hub for the manufacturing of Roche’s continuous glucose monitoring (CGM) systems marking a new milestone in Roche’s long history of revolutionizing healthcare across the globe.

Indianapolis serves as the North American headquarters for Roche Diagnostics, part of the Roche Group – the world’s largest biotech company. This latest expansion underscores Roche’s commitment to advancing science, driving innovation, and delivering cutting-edge solutions that improve patient outcomes.

The Indianapolis campus houses key operations, including U.S. research and development, laboratories, manufacturing, distribution, IT and administrative functions. It currently produces approximately 5.2 billion Accu-Chek ^® diabetes test strips annually and serves as one of two global distribution hubs focused on serving the U.S. market and supporting distribution to 53 countries worldwide.

Building on more than $800 million in U.S. investments made at Roche U.S. sites since 2015, this new commitment reinforces Roche’s long term dedication to U.S. operations and highlights the country’s central role in the company’s global strategy.

The expansion is expected to generate hundreds of highly-skilled manufacturing jobs and thousands of construction jobs, providing a significant boost to Indiana’s economy. It will also enhance domestic production capabilities and reduce dependency on imports – aligning with national efforts to strengthen local manufacturing.